Revenue grew 7.3% to ¥14.11 billion and net profit surged 27.8% to ¥2.40 billion in H1 2024, led by strong CHC business growth, while prescription drug sales declined. Management expects full-year revenue to exceed industry average, but notes policy and market risks.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.